Vikram Purohit
Stock Analyst at Morgan Stanley
(0.82)
# 3,938
Out of 4,983 analysts
156
Total ratings
29.51%
Success rate
-12.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $2.70 | +118.15% | 3 | Aug 18, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $75 → $80 | $75.85 | +5.47% | 9 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $4.84 | +3.31% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $197.24 | +26.75% | 19 | May 5, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $69 → $65 | $83.90 | -22.53% | 24 | Mar 24, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $114.10 | +66.52% | 19 | Feb 27, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $40 → $35 | $18.24 | +91.89% | 2 | Dec 11, 2024 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $4.90 | +83.67% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $28.24 | +9.77% | 2 | Sep 11, 2024 | |
| ABVX ABIVAX Société Anonyme | Maintains: Equal-Weight | $15 → $16 | $82.28 | -80.55% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $5.10 | +488.24% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $16.97 | -41.07% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $2.34 | +156.41% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $9.26 | +353.56% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $48.78 | -15.95% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $23.05 | +73.54% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $2.62 | +396.18% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $19.11 | +98.85% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $11.55 | +73.16% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $13.87 | -27.90% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.72 | +1,179.07% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $9.84 | +103.25% | 2 | Aug 5, 2020 |
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $2.70
Upside: +118.15%
Halozyme Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $75 → $80
Current: $75.85
Upside: +5.47%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $4.84
Upside: +3.31%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $197.24
Upside: +26.75%
Incyte
Mar 24, 2025
Maintains: Equal-Weight
Price Target: $69 → $65
Current: $83.90
Upside: -22.53%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $114.10
Upside: +66.52%
Zenas BioPharma
Dec 11, 2024
Maintains: Overweight
Price Target: $40 → $35
Current: $18.24
Upside: +91.89%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $4.90
Upside: +83.67%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $28.24
Upside: +9.77%
ABIVAX Société Anonyme
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $82.28
Upside: -80.55%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $5.10
Upside: +488.24%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $16.97
Upside: -41.07%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $2.34
Upside: +156.41%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $9.26
Upside: +353.56%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $48.78
Upside: -15.95%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $23.05
Upside: +73.54%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $2.62
Upside: +396.18%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $19.11
Upside: +98.85%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $11.55
Upside: +73.16%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $13.87
Upside: -27.90%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.72
Upside: +1,179.07%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $9.84
Upside: +103.25%